Hi Tech Pharmacal (NAS: HITK) is expected to report Q3 earnings on March 7. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hi Tech Pharmacal's revenues will grow 8.7% and EPS will decrease -10.1%.
The average estimate for revenue is $60.5 million. On the bottom line, the average EPS estimate is $0.71.
Last quarter, Hi Tech Pharmacal tallied revenue of $57.5 million. GAAP reported sales were 1.2% higher than the prior-year quarter's $56.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.66. GAAP EPS of $0.66 for Q2 were 37% lower than the prior-year quarter's $1.04 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 51.4%, 730 basis points worse than the prior-year quarter. Operating margin was 22.6%, much worse than the prior-year quarter. Net margin was 15.5%, 870 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $235.1 million. The average EPS estimate is $2.62.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 204 members out of 219 rating the stock outperform, and 15 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Hi Tech Pharmacal a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hi Tech Pharmacal is outperform, with an average price target of $36.83.
Add Hi Tech Pharmacal to My Watchlist.
The article Does The Street Have Hi Tech Pharmacal Figured Out? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.